NCT06291779

Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine

Development of Pancreatic Cancer Diagnostic Method by Using a Reagent for Analyzing Purine Metabolite (Hypoxanthine, Xanthine) in Urine

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 120 (estimated)
• Sponsor: Ho-Seong Han · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

* This study aim to develope a diagnostic method of pancreatic cancer by using a reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine. * It is safe and cost effective compare to radiologic or blood test. It can be used for initial screening test for healty population.

Detailed description

* CubeBio and Seoul National University Bundang Hospital signed a joint technology development agreement to compare the analytical performance of existing analytical methods and purine metabolite analysis reagents developed by CubeBio. * Through quantitative analysis of hypoxanthine and xanthine in the urine of normal people and pancreatic cancer patients, we plan to confirm the possibility of diagnosing pancreatic cancer using reagents for analyzing purine metabolites. * Early diagnosis of pancreatic cancer is a key determinant of cure and survival rates, and impact on all aspects of cancer, including rate of progression, treatment, and prognosis. * This study could change the paradigm of pancreatic cancer screening by evaluating the stability and accuracy of urinary purine metabolite analysis reagents.

Conditions

• Pancreas Cancer
• Diagnosis

Interventions

Type	Name	Description
DEVICE	Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio	* Collect urine from the patient to measure urinary hypoxia, xanthine concentration. * Hypoxic acid, xanthine analysis in urine using High Performance Liquid Chromatography (HPLC). * After that, hypoxanthine and xanthine will be analyzed using purine metabolite analysis reagents. * Compare the cutoff of the metabolic value of Pancreas cancer clarified in the existing research and the value of the sample.

Timeline

• Start date: 2022-11-30
• Primary completion: 2024-02-26
• Completion: 2024-05-31
• First posted: 2024-03-04
• Last updated: 2024-03-04

Locations

1 site across 1 country: South Korea